CogMol: Target-Specific and Selective Drug Design for COVID-19 Using Deep Generative Models
Vijil Chenthamarakshan, Payel Das, Samuel C. Hoffman, Hendrik Strobelt, Inkit Padhi, Kar Wai Lim, Benjamin Hoover, Matteo Manica, Jannis Born, Teodoro Laino, Aleksandra Mojsilovic
Abstract
The novel nature of SARS-CoV-2 calls for the development of efficient de novo drug design approaches. In this study, we propose an end-to-end framework, named CogMol (Controlled Generation of Molecules), for designing new drug-like small molecules targeting novel viral proteins with high affinity and off-target selectivity. CogMol combines adaptive pre-training of a molecular SMILES Variational Autoencoder (VAE) and an efficient multi-attribute controlled sampling scheme that uses guidance from attribute predictors trained on latent features. To generate novel and optimal drug-like molecules for unseen viral targets, CogMol leverages a protein-molecule binding affinity predictor that is trained using SMILES VAE embeddings and protein sequence embeddings learned unsupervised from a large corpus. We applied the CogMol framework to three SARS-CoV-2 target proteins: main protease, receptor-binding domain of the spike protein, and non-structural protein 9 replicase. The generated candidates are novel at both the molecular and chemical scaffold levels when compared to the training data. CogMol also includes in silico screening for assessing toxicity of parent molecules and their metabolites with a multi-task toxicity classifier, synthetic feasibility with a chemical retrosynthesis predictor, and target structure binding with docking simulations. Docking reveals favorable binding of generated molecules to the target protein structure, where 87-95% of high affinity molecules showed docking free energy < -6 kcal/mol. When compared to approved drugs, the majority of designed compounds show low predicted parent molecule and metabolite toxicity and high predicted synthetic feasibility. In summary, CogMol can handle multi-constraint design of synthesizable, low-toxic, drug-like molecules with high target specificity and selectivity, even to novel protein target sequences, and does not need target-dependent fine-tuning of the framework or target structure information.
Ask about this paper
Your agent reads all of it.
Lune indexed this paper to the last equation, along with the top-tier papers that cite it. Ask a question and the answer quotes them.
Your agent calls
Luneget_paper_fulltext
Free to start. No credit card required.
Terminal
Install the CLIlune papers fulltext 781e6b34-d475-4ec2-b8bf-159cc5b64a02Cited by top-tier papers6
- Design Principles for Generative AI ApplicationsJustin D. Weisz, Jessica He, Michael J. Muller, Gabriela Hoefer et al.CHI 2024 · 221 citations
- Retrieval-based Controllable Molecule GenerationZichao Wang, Weili Nie, Zhuoran Qiao, Chaowei Xiao et al.ICLR 2023 · 8 citations
- CombiMOTS: Combinatorial Multi-Objective Tree Search for Dual-Target Molecule GenerationThibaud Southiratn, Bonil Koo, Yijingxiu Lu, Sun KimICML 2025
- Steering Large Language Models through the DMTA Cycle: Structure-Based Drug Design via Knowledge-Driven Bi-Level Thompson SamplingXuanning Hu, Hao Tuo, Jinglong Ji, Anchen Li et al.ICML 2026
- Sign Rank Limitations for Inner Product Graph DecodersSu Hyeong Lee, Qingqi Zhang, Risi KondorICML 2024
Related papers
- GxVAEs: Two Joint VAEs Generate Hit Molecules from Gene Expression ProfilesChen Li, Yoshihiro YamanishiAAAI 2024 · 14 citations
- De novo Drug Design using Reinforcement Learning with Multiple GPT AgentsXiuyuan Hu, Guoqing Liu, Yang Zhao, Hao ZhangNeurIPS 2023 · 42 citations
- Path-Aware and Structure-Preserving Generation of Synthetically Accessible MoleculesJuhwan Noh, Dae-Woong Jeong, Kiyoung Kim, Sehui Han et al.ICML 2022 · 11 citations
- Pocket2Mol: Efficient Molecular Sampling Based on 3D Protein PocketsXingang Peng, Shitong Luo, Jiaqi Guan, Qi Xie et al.ICML 2022 · 291 citations
- GenMol: A Drug Discovery Generalist with Discrete DiffusionSeul Lee, Karsten Kreis, Srimukh Prasad Veccham, Meng Liu et al.ICML 2025
